Bellevue Group’s BeOne Medicines Ltd ONC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.13M | Buy |
3,812
+1,922
| +102% | +$622K | 0.03% | 88 |
|
|
2025
Q4 | $574K | Sell |
1,890
-31,907
| -94% | -$10.4M | 0.01% | 128 |
|
|
2025
Q3 | $11.5M | Sell |
33,797
-4,901
| -13% | -$1.49M | 0.24% | 60 |
|
|
2025
Q2 | $9.37M | Buy |
38,698
+3,369
| +10% | +$826K | 0.21% | 67 |
|
|
2025
Q1 | $9.62M | Buy |
35,329
+1,100
| +3% | +$257K | 0.22% | 75 |
|
|
2024
Q4 | $6.32M | Sell |
34,229
-24,500
| -42% | -$5.01M | 0.12% | 90 |
|
|
2024
Q3 | $13.2M | Buy |
58,729
+33,100
| +129% | +$5.96M | 0.21% | 83 |
|
|
2024
Q2 | $3.66M | Buy |
25,629
+700
| +3% | +$108K | 0.06% | 100 |
|
|
2024
Q1 | $3.9M | Sell |
24,929
-3,671
| -13% | -$591K | 0.06% | 101 |
|
|
2023
Q4 | $5.21M | Sell |
28,600
-24,600
| -46% | -$4.45M | 0.08% | 95 |
|
|
2023
Q3 | $9.5M | Buy |
53,200
+43,000
| +422% | +$8.51M | 0.15% | 93 |
|
|
2023
Q2 | $1.82M | Sell |
10,200
-48,035
| -82% | -$11.1M | 0.03% | 116 |
|
|
2023
Q1 | $12.6M | Buy |
58,235
+23,735
| +69% | +$5.69M | 0.18% | 91 |
|
|
2022
Q4 | $7.71M | Buy |
34,500
+27,500
| +393% | +$5.04M | 0.1% | 103 |
|
|
2022
Q3 | $940K | Buy |
+7,000
| New | +$1.2M | 0.01% | 139 |
|
|
2022
Q1 | – | Sell |
-23,000
| Closed | -$6.23M | – | 203 |
|
|
2021
Q4 | $6.23M | Hold |
23,000
| – | – | 0.06% | 121 |
|
|
2021
Q3 | $8.35M | Sell |
23,000
-61,300
| -73% | -$20M | 0.08% | 121 |
|
|
2021
Q2 | $28.9M | Buy |
84,300
+24,600
| +41% | +$8.15M | 0.28% | 95 |
|
|
2021
Q1 | $20.8M | Sell |
59,700
-47,400
| -44% | -$15.7M | 0.22% | 98 |
|
|
2020
Q4 | $27.7M | Buy |
107,100
+67,700
| +172% | +$18.6M | 0.32% | 84 |
|
|
2020
Q3 | $11.3M | Sell |
39,400
-18,600
| -32% | -$4.37M | 0.16% | 103 |
|
|
2020
Q2 | $10.9M | Sell |
58,000
-500
| -0.9% | -$81.4K | 0.15% | 101 |
|
|
2020
Q1 | $7.2M | Buy |
58,500
+11,644
| +25% | +$1.82M | 0.14% | 102 |
|
|
2019
Q4 | $7.77M | Sell |
46,856
-25,244
| -35% | -$4.19M | 0.12% | 103 |
|
|
2019
Q3 | $8.98M | Sell |
72,100
-20,900
| -22% | -$2.78M | 0.17% | 91 |
|
|
2019
Q2 | $11.5M | Sell |
93,000
-9,200
| -9% | -$1.17M | 0.2% | 80 |
|
|
2019
Q1 | $13.5M | Buy |
102,200
+18,600
| +22% | +$2.51M | 0.74% | 46 |
|
|
2018
Q4 | $11.7M | Buy |
83,600
+71,980
| +619% | +$9.55M | 0.77% | 38 |
|
|
2018
Q3 | $2M | Buy |
11,620
+120
| +1% | +$20.2K | 0.13% | 105 |
|
|
2018
Q2 | $1.77M | Sell |
11,500
-29,150
| -72% | -$5.2M | 0.15% | 92 |
|
|
2018
Q1 | $6.83M | Sell |
40,650
-63,000
| -61% | -$8.53M | 0.68% | 51 |
|
|
2017
Q4 | $10.1M | Buy |
+103,650
| New | +$9.49M | 1.06% | 37 |
|
Other funds holding ONC
BBA
HA
Bellevue Group's ONC Position: Q1 2026 in Review
Bellevue Group increased its BeOne Medicines Ltd (ONC) stake by 102% in Q1 2026, buying an estimated $622K and bringing the position to 3,812 shares worth $1.13M. The position accounts for 0.03% of the portfolio, ranked #88.
Bellevue Group first reported a position in ONC in Q4 2017 and has held it in 32 quarters since. The position peaked at $28.9M in Q2 2021. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.
- Bellevue Group held 3,812 shares of BeOne Medicines Ltd worth $1.13M as of Q1 2026.
- Bellevue Group bought 1,922 BeOne Medicines Ltd shares in Q1 2026, an estimated $622K.
- BeOne Medicines Ltd made up 0.03% of Bellevue Group's portfolio in Q1 2026, its #88 holding.
- Bellevue Group first reported a position in BeOne Medicines Ltd in Q4 2017 and has held it in 32 quarters since.
- Bellevue Group's BeOne Medicines Ltd position peaked at $28.9M in Q2 2021.
- 281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.